Navigation Links
EastBridge Investment Group Announces Completion of its Merger with Cellular Biomedicine Group - Shareholder Conference Call to be held February 8th
Date:2/7/2013

PHOENIX, Feb. 7, 2013 /PRNewswire/ --EastBridge Investment Group Corporation (EBIG), a provider of financial consulting services to companies in Asia and the United States ("EBIG"), today announced that on February 6, EBIG and Cellular Biomedicine Group ("CBMG") executed all documentation and filed the Articles of Merger with the Registry of Corporate Affairs of the British Virgin Islands with respect to the consummation of the merger of CBMG with CBMG Acquisition Limited, a wholly-owned subsidiary of EBIG. The merged company is a wholly-owned subsidiary of EBIG.  EBIG continues to operate under the corporate name "EastBridge Investment Group Corporation", a Delaware corporation, and its common stock continues to be quoted on the OTCQB under stock symbol "EBIGD".  

A shareholder conference call is scheduled for February 8, 2013, at 11:00am EST, for questions and answers with the new corporate management team of EastBridge. Dial-in numbers for both domestic and international calls are listed below. You may also listen to a replay of the conference call by dialing the appropriate number and access code below. A replay of the conference call will be available on the company's website following the call.

Participants Dial-In Numbers

Toll-Free (US & Canada) (888) 390-3983

International (201) 604-5105

Dialing In For Conference Recording Playback

1. Dial 888-632-8973, or 585-295-6791 if you are calling from outside the USA.

2. At the system prompt, dial your replay code (80529152) followed by the # sign.

About Cellular Biomedicine Group
Cellular Biomedicine Group, Ltd. develops proprietary cell therapies for the treatment of certain cancer and degenerative diseases. Our developmental stem cell, progenitor cell, and immune cell projects are the result of collaborative research and development between scientists and doctors from the U.S. and China. Our flagship GMP facility, consisting of eight independent cell production lines, is designed, certified and managed according to U.S. standards. To learn more about CBMG, please visit: www.cellbiomedgroup.com

About EastBridge
EastBridge Investment Group focuses on high-growth companies in Asia and in the United States, offering assistance with all aspects of IPOs, joint ventures and merchant banking services. EastBridge targets industries in the fields of electronics, real estate, auto, metal, energy, environmental, bioscience and retail food distribution. To learn more about EastBridge Investment Group go to our web site: www.EbigCorp.com. To receive EBIG's email alert, send a blank email to info@EbigCorp.com.

Forward-Looking Statements
Statements in this press release relating to plans, strategies, trends, specific activities or investments, and other statements that are not descriptions of historical facts may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking information is inherently subject to risks and uncertainties, and actual results could differ materially from those currently anticipated due to a number of factors, which include, but are not limited to, risk factors inherent in doing business. Forward-looking statements may be identified by terms such as "may," "will," "expects," "plans," "intends," "estimates," "potential," or "continue," or similar terms or the negative of these terms. Although EastBridge and CBMG believe the expectations reflected in the forward-looking statements are reasonable, they cannot guarantee that future results, levels of activity, performance or achievements will be obtained. Neither EastBridge nor CBMG has any obligation to update these forward-looking statements other than as required by law.

Contact:
Jeff Ramson
Investor Relations
ProActive Capital Group
646-863-6341

Sarah Kelly
Director of Corporate Communications, CBMG
sarah.kelly@cellbiomedgroup.com


'/>"/>
SOURCE EastBridge Investment Group Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. EastBridge Investment Group and CBMG attended SeeThruEquity Investor Conference in New York
2. Patheon Announces First Phase of Additional Investment in Milton Park, UK Facility to Expand Early Development Capabilities in Europe
3. Axela Inc. Retains Investment Bank to Evaluate Strategic Opportunities
4. Analysis of Venture Capital Investment Trends in the North American and European Healthcare Industry
5. Kansas Bioscience Authority Approves $700,000 in Investments
6. David Lichtenstein: Biotechnology is Rich Area for Investment
7. Israeli Ministry of Finance Hosts Israel Investment, Innovation and Trade Forum in New York
8. Foundation Venture Capital Group Makes Eighth Start-Up Investment
9. Regenerative Sciences Receives $2M Investment for Orthopedic Stem Cell Initiatives
10. Enox Biopharma, Inc. Will Present at IN360 Investment in Innovation Conference
11. City of Mason and Top Gun Sales Performance Announce $4 Million Investment In New Corporate Headquarters
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... Palo Alto, CA, USA (PRWEB) , ... October 11, 2017 , ... ... is set to take place on 7th and 8th June 2018 in San Francisco, ... and policy influencers as well as several distinguished CEOs, board directors and government officials ...
(Date:10/11/2017)... TX (PRWEB) , ... October 11, 2017 , ... ... August compared the implantation and pregnancy rates in frozen and fresh in ... contribution of progesterone and maternal age to IVF success. , After comparing the ...
(Date:10/10/2017)... ... , ... Dr. Bob Harman, founder and CEO of VetStem Biopharma, Inc. ... The event entitled “Stem Cells and Their Regenerative Powers,” was held on August ... MPVM was joined by two human doctors: Peter B. Hanson, M.D., Chief of Orthopedic ...
(Date:10/9/2017)... 9, 2017  BioTech Holdings announced today identification ... its ProCell stem cell therapy prevents limb loss ... Company, demonstrated that treatment with ProCell resulted in ... as compared to standard bone marrow stem cell ... in reduction of therapeutic effect.  ...
Breaking Biology Technology:
(Date:4/18/2017)... a global expert in SoC-based imaging and computing solutions, has developed ... the company,s hybrid codec technology. A demonstration utilizing TeraFaces ® , ... showcased during the upcoming Medtec Japan at Tokyo Big Sight April ... Vegas Convention Center April 24-27. ... Click here for an image of the M820 ...
(Date:4/13/2017)... April 13, 2017 UBM,s Advanced Design and ... will feature emerging and evolving technology through its 3D ... will run alongside the expo portion of the event ... and demonstrations focused on trending topics within 3D printing ... and manufacturing event will take place June 13-15, 2017 at ...
(Date:4/11/2017)... , April 11, 2017 Crossmatch®, a ... authentication solutions, today announced that it has been ... Research Projects Activity (IARPA) to develop next-generation Presentation ... "Innovation has been a driving force ... program will allow us to innovate and develop ...
Breaking Biology News(10 mins):